Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Substituted pyridines and pyridazines able to inhibit angiogenesis

Classifications

C07D401/12 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
View 13 more classifications

Landscapes

Chemical & Material Sciences Organic Chemistry
Show more

UA75053C2

Ukraine

Download PDF Find Prior Art Similar
Other languages
English
Ukrainian
Worldwide applications
2000 GT CO AR DO PA MY TW MY PE MY AT PL RU EE RS CZ IL BR UA MX HR AU CN DE KR CN CA EP JP NZ CN ES HU KR WO KR SK 2002 NO ZA BG MA 2008 IL IL 2011 AR AR
Application UA2002043504A events
2000-09-26
Application filed by Bayer Corp
2006-03-15
Publication of UA75053C2
Info
Patent citations (12)
Cited by (36)
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
Discuss

Patent Citations (12)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
FR1453897A * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
CN1151136C * 1994-08-09 2004-05-26 卫材株式会社 缩合哒嗪系化合物
IL118631A * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
DE69942097D1 * 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
AU766081B2 * 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
DE60110749T2 * 2000-02-09 2006-02-02 Novartis Ag Pyridinderivative als angiogenese- und/oder vegf-rezeptor-tyrosinkinase-inhibitoren
* Cited by examiner, † Cited by third party

Cited By (36)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
AU7993801A * 2000-08-09 2002-02-18 Astrazeneca Ab Chemical compounds
AU2001295986B2 2000-10-20 2006-08-17 Eisai R&D Management Co., Ltd Nitrogenous aromatic ring compounds
JP2006503796A * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
TWI299664B 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
ES2318276T3 * 2003-03-11 2009-05-01 Novartis Ag Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map.
JPWO2004089412A1 * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤
JP4303726B2 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR100553398B1 * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
EP2364699A1 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US9006240B2 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US8304406B2 2006-04-15 2012-11-06 Bayer Intellectual Property Gmbh Compounds for treating pulmonary hypertension
JP5190361B2 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
EP2065372B1 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CA2704000C 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
RU2560683C2 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
BR112013021941B1 2011-04-18 2022-11-16 Eisai R & D Management Co., Ltd Agente terapêutico para tumor
ES2841809T3 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
MX2015004979A 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
CA2912219C 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
KR102329681B1 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
FI3263106T3 2015-02-25 2024-01-03 Eisai R&D Man Co Ltd Menetelmä kinoliinijohdannaisen kitkeryyden tukahduttamiseksi
WO2016140717A1 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
KR102705821B1 2015-06-16 2024-09-12 가부시키가이샤 프리즘 바이오랩 항암제
MX381976B 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN110072528B 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN107129502B * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CN110831597A 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗
US20220213097A1 * 2019-04-22 2022-07-07 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN112830932B * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
KR20240115979A 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication Publication Date Title
UA75053C2 2006-03-15 Substituted pyridines and pyridazines able to inhibit angiogenesis
ES2968810T3 2024-05-14 Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP6141866B2 2017-06-07 置換ベンジルピラゾール類
JP2016514719A 2016-05-23 ヘテロアリール置換インダゾール
JP2015520143A 2015-07-16 癌を治療するためのｂｕｂ１阻害薬としての置換されているシクロアルケノピラゾール類
JP2016525075A 2016-08-22 ヘテロアリール置換ピラゾール類
WO2007037534A1 2007-04-05 ２－へテロアリール置換インドール誘導体
JP2016525076A 2016-08-22 置換されたベンジルピラゾール類
JP2003522773A 2003-07-29 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体
TW200829589A 2008-07-16 Compound for inhibiting mitotic progression
EA018964B1 2013-12-30 СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
JP6850361B2 2021-03-31 キナーゼを選択的に阻害する化合物及びその使用
AU775237B2 2004-07-22 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
US6689883B1 2004-02-10 Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US20110263597A1 2011-10-27 Substituted pyridines and pyridazines with angiogenesis inhibiting activity
TWI817955B 2023-10-11 芳香類衍生物、其製備方法及其在醫藥上的應用
EP2646445B1 2016-03-16 Oxazolo[5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
CN117756812A 2024-03-26 一类prmt5抑制剂及其用途
WO2017034242A2 2017-03-02 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
WO2010131738A1 2010-11-18 アゼチジン化合物およびその医薬用途
CN104788423B 2016-10-26 一种新的囊性纤维化跨膜传导调节因子抑制剂
JP2005533109A 2005-11-04 高増殖性障害の処置のためのフロピリジン及びフロピリミジン誘導体
CN116096721A 2023-05-09 作为新型选择性flt3抑制剂的1h-咪唑并[4,5-h]喹唑啉化合物
CN119798282A 2025-04-11 基于稠合吡啶环的Myt1抑制剂
CN107163061A 2017-09-15 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用

Priority And Related Applications

Applications Claiming Priority (2)

Application Filing date Title
US40760099A 1999-09-28
PCT/US2000/026500 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
angiogenesis title,claims,abstract,description 25 0.000
pyridines title,abstract,description 7 0.000
pyridazines title,abstract,description 5 0.000
method claims,abstract,description 131 0.000
substituent group claims,abstract,description 72 0.000
cycloalkyl group claims,abstract,description 27 0.000
aryl group claims,abstract,description 22 0.000
phenyl group claims,abstract,description 22 0.000
Mammalia claims,abstract,description 9 0.000
abnormal effect claims,abstract,description 8 0.000
process claims,abstract,description 8 0.000
pyridyl group claims,abstract,description 8 0.000
pharmaceutical composition claims,abstract,description 7 0.000
alkyl group claims,description 192 0.000
compounds claims,description 136 0.000
amino group claims,description 103 0.000
fragment claims,description 103 0.000
atom claims,description 87 0.000
Methanol claims,description 77 0.000
amino- claims,description 68 0.000
heteroarylalkyl group claims,description 63 0.000
methyl group claims,description 53 0.000
carbon atom claims,description 52 0.000
primary amino group claims,description 49 0.000
heterocyclic group claims,description 48 0.000
heteroaryl group claims,description 40 0.000
carboacyl group claims,description 33 0.000
halogen claims,description 33 0.000
halogens claims,description 31 0.000
substituted aryl group claims,description 28 0.000
carbon claims,description 27 0.000
oxygen claims,description 25 0.000
biosynthetic process claims,description 24 0.000
Guanidine claims,description 23 0.000
hydroxy group claims,description 20 0.000
salts claims,description 19 0.000
amidines claims,description 18 0.000
amines claims,description 18 0.000
sulfo group claims,description 17 0.000
alkenyl group claims,description 16 0.000
alkyl amino group claims,description 15 0.000
cycloalkenyl group claims,description 15 0.000
alkyl sulfonyl group claims,description 14 0.000
heterocycloalkyl group claims,description 12 0.000
N-methyl-guanidine claims,description 11 0.000
dimethylaminoamidine claims,description 11 0.000
heteroatom claims,description 11 0.000
alkoxy group claims,description 10 0.000
alkylene group claims,description 10 0.000
bicyclic group claims,description 10 0.000
permeability claims,description 10 0.000
nitrogen group claims,description 9 0.000
oxygen atom claims,description 9 0.000
pyridazine claims,description 9 0.000
cyano group claims,description 8 0.000
disease claims,description 8 0.000
diseases, disorders, signs and symptoms claims,description 8 0.000
alkoxycarbonyl group claims,description 7 0.000
nitro group claims,description 7 0.000
prodrug claims,description 7 0.000
prodrug claims,description 7 0.000
guanidinium claims,description 6 0.000
rheumatoid arthritis claims,description 6 0.000
hydrogen claims,description 5 0.000
pathological effect claims,description 5 0.000
thiol group claims,description 5 0.000
Dermatitis herpetiformis claims,description 4 0.000
Diabetic retinopathy claims,description 4 0.000
Erythema multiforme claims,description 4 0.000
Pemphigoid claims,description 4 0.000
Psoriasis claims,description 4 0.000
Retinal disease claims,description 4 0.000
Retinopathy claims,description 4 0.000
Retinopathy of prematurity claims,description 4 0.000
age-related macular degeneration claims,description 4 0.000
bullous pemphigoid claims,description 4 0.000
drug carrier claims,description 4 0.000
ischemic effect claims,description 4 0.000
macular degeneration claims,description 4 0.000
retinal vein occlusion claims,description 4 0.000
trifluoromethoxy group claims,description 4 0.000
trifluoromethyl group claims,description 4 0.000
tumor growth claims,description 4 0.000
ring segment claims,description 2 0.000
anilino group claims 4 0.000
Strigiformes claims 3 0.000
catfish claims 3 0.000
pyridazin-4-amine claims 3 0.000
4-chlorobenzenesulfonate claims 1 0.000
Hydrogen bromide claims 1 0.000
NO3 claims 1 0.000
Nitrate claims 1 0.000
Phenol claims 1 0.000
Sulfate claims 1 0.000
furosemide claims 1 0.000
isethionic acid claims 1 0.000
methoxy group claims 1 0.000
pyridazin-4-yl group claims 1 0.000
toluene-4-sulfonate claims 1 0.000
topography claims 1 0.000
material abstract,description 8 0.000
inhibitory effect abstract,description 3 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services